Sign In
Buy STTK
$7.92
+0.630 (+8.64%)
At Close: Aug 04, 2026
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients
What Makes Shattuck Labs (STTK) a New Buy Stock
01:01pm, Tuesday, 07'th May 2024
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
10:56am, Tuesday, 07'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
09:31am, Thursday, 02'nd May 2024
Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.49 per share a year ago.
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:05am, Thursday, 02'nd May 2024
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at th
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired res
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
07:00am, Monday, 01'st Apr 2024
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.
07:00am, Monday, 04'th Mar 2024
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pr
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
04:05pm, Thursday, 29'th Feb 2024
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontlin
Shattuck Labs Announces Participation in Upcoming March Conferences
07:00am, Monday, 26'th Feb 2024
AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
05:06am, Wednesday, 14'th Feb 2024
OSAKA, Japan , Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pro
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
07:00am, Monday, 08'th Jan 2024
AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Thursday, 04'th Jan 2024
AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs: Positive Blood Cancer Data Leads To Mid-2024 Catalyst
06:58pm, Thursday, 21'st Dec 2023
Positive results were released from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line higher-risk myelodysplastic syndrome and TP53 mu
